Cerus (CERS) PT Raised to $7.50 at Wedbush on FDA Approval
Tweet Send to a Friend
Wedbush analyst Zarak Khurshid reiterated an Outperform rating and boosted his price target on Cerus (NASDAQ: CERS) to $7.50 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
